Post-Trade Analysis: Pacific Biosciences of California Inc (PACB) Slides -7.73, Closing at 1.79

Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $1.94 in the prior trading day, Pacific Biosciences of California Inc (NASDAQ: PACB) closed at $1.79, down -7.73%. In other words, the price has decreased by -$7.73 from its previous closing price. On the day, 8.04 million shares were traded. PACB stock price reached its highest trading level at $2.02 during the session, while it also had its lowest trading level at $1.78.

Ratios:

Our goal is to gain a better understanding of PACB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.36 and its Current Ratio is at 9.28. In the meantime, Its Debt-to-Equity ratio is 1.44 whereas as Long-Term Debt/Eq ratio is at 1.42.

On April 18, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $7 to $2.50.

On December 14, 2023, Stephens started tracking the stock assigning a Overweight rating and target price of $11.Stephens initiated its Overweight rating on December 14, 2023, with a $11 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 20 ’24 when Farmer Michele sold 5,275 shares for $2.03 per share. The transaction valued at 10,708 led to the insider holds 211,941 shares of the business.

Meline David W bought 40,000 shares of PACB for $176,160 on Mar 06 ’24. The Director now owns 40,000 shares after completing the transaction at $4.40 per share. On Mar 04 ’24, another insider, HENRY CHRISTIAN O, who serves as the insider of the company, sold 14,177 shares for $4.87 each. As a result, the insider received 69,056 and left with 2,596,670 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 487517216 and an Enterprise Value of 856969024. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.43 while its Price-to-Book (P/B) ratio in mrq is 0.75. Its current Enterprise Value per Revenue stands at 4.276 whereas that against EBITDA is -3.033.

Stock Price History:

Over the past 52 weeks, PACB has reached a high of $14.55, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is -24.78%, while the 200-Day Moving Average is calculated to be -72.46%.

Shares Statistics:

The stock has traded on average 10.97M shares per day over the past 3-months and 8233960 shares per day over the last 10 days, according to various share statistics. A total of 267.74M shares are outstanding, with a floating share count of 264.29M. Insiders hold about 2.96% of the company’s shares, while institutions hold 92.38% stake in the company. Shares short for PACB as of 1715731200 were 56581081 with a Short Ratio of 5.16, compared to 1713139200 on 48520230. Therefore, it implies a Short% of Shares Outstanding of 56581081 and a Short% of Float of 23.93.

Most Popular